Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Solute carrier (SLC) transporters facilitate the cellular uptake of endogenous compounds and xenobiotics.
• These transporters are crucial in drug absorption and elimination, particularly in the gastrointestinal tract, liver, and kidneys.
• SLC transporters are also present in cancer target organs, affecting drug sensitivity and treatment toxicity.

Purpose of the Study:

• To review the role of SLC transporters in the disposition of anticancer drugs.
• To highlight the impact of transporters on drug efficacy and toxicity.
• To discuss the potential of transport inhibitors in combinatorial cancer therapy.

Main Methods:

• Literature review focusing on SLC transporters and major anticancer drug classes.
• Analysis of studies investigating transporter-mediated drug disposition and clinical outcomes.
• Synthesis of current research on transporter inhibitors for cancer treatment.

Main Results:

• SLC transporters significantly influence the absorption, distribution, metabolism, and excretion of anticancer agents like taxanes, platinum derivatives, nucleoside analogs, and anthracyclines.
• Transporter expression levels in tumors and healthy organs correlate with drug efficacy and the incidence of side effects.
• Emerging data supports the use of transport inhibitors to modulate drug exposure and reduce toxicity.

Conclusions:

• A deeper understanding of SLC transporter roles is essential for optimizing anticancer drug therapy.
• Targeting SLC transporters offers a promising strategy to enhance treatment efficacy and minimize adverse events.
• Further research into transporter-drug interactions will guide the development of safer and more effective combination therapies.